Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of contezolid acefosamil/contezolid versus linezolid for moderate or severe diabetic foot infection
MOH_2022-12-18_012240Phase 3Completed
- Sponsor
- MicuRx Pharmaceuticals
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diabetic foot infection (DFI) comparing Contezolid acefosamil/contezolid with Linezolid (2 arms). Primary endpoint: Clinical response at Day 35. Started Sep 2022; status: completed.
02
Drugs
contezolid acefosamilcontezolidlinezolid
03
Conditions
diabetic foot infection (DFI)
Beyond the preview
Go deeper on MOH_2022-12-18_012240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-12-18_012240.